Benitec Biopharma Return on Investment 2014-2022 | BNTC

Current and historical return on investment (ROI) values for Benitec Biopharma (BNTC) over the last 10 years.
Benitec Biopharma ROI - Return on Investment Historical Data
Date TTM Net Income LT Investments & Debt Return on Investment
2022-09-30 $-0.02B $0.02B -189.47%
2022-06-30 $-0.02B $0.00B -184.62%
2022-03-31 $-0.02B $0.01B -188.89%
2021-12-31 $-0.02B $0.01B -184.62%
2021-09-30 $-0.02B $0.02B -152.38%
2021-06-30 $-0.01B -164.71%
2021-03-31 $-0.01B $0.01B -118.18%
2020-12-31 $-0.01B $0.02B -133.33%
2020-06-30 $-0.01B $0.01B -96.00%
2020-03-31 $-0.01B -133.33%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.006B $0.000B
Benitec Biopharma Limited is a biotechnology company which developed a patented gene silencing technology delivered by gene therapy called DNA directed RNA interference. The company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis C and B, drug resistant lung cancer and wet age-related macular degeneration. Benitec Biopharma Limited is based in Sydney, Australia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $158.293B 9.67
GSK (GSK) United Kingdom $71.300B 9.41
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.249B 19.20
Ginkgo Bioworks Holdings (DNA) United States $3.996B 0.00
Myovant Sciences (MYOV) United Kingdom $2.614B 0.00
Arcus Biosciences (RCUS) United States $1.485B 22.29
Biohaven (BHVN) United States $1.240B 0.00
Emergent Biosolutions (EBS) United States $0.697B 5.48
ADC Therapeutics SA (ADCT) Switzerland $0.356B 0.00
Enzo Biochem (ENZ) United States $0.070B 0.00
Ambrx Biopharma (AMAM) United States $0.070B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.024B 0.00